GeneDx rises after Q3 results beat market estimates

GeneDx Holdings

28/10/2025 18:20

Updates

** Genetic testing company GeneDx's WGS.O shares rise 11% to $145.51, hitting highest level in over three years

** Co posts Q3 revenue of $116.7 mln, above analysts' estimates of $104.1 mln

** Co's adj EPS for Q3 also beats estimates

** WGS raises full-year 2025 revenue forecast to $425 mln-$428 mln vs earlier forecast of $400 mln-$415 mln

** Eight out of 9 analysts rate stock "buy" or higher, one "hold"; median PT is $125

** As of last close, WGS was up 70% YTD

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))